Antares Pharma — UBS Global Life Sciences Conference 2004
31 slides from Antares Pharma's conference presentation, Sep 28, 2004
Slide 1: Antares Pharma, Inc.
Antares Pharma, Inc. Amex: AIS www.antarespharma.com UBS Global Life Sciences Conference September 28, 2004
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements which are not s
Slide 3: Agenda
Agenda Overview Products, Platforms and Pipelines Alliances, Partnerships and Markets Financial Overview Summary
Slide 4: Overview
Overview 4e antares a
Slide 5: Antares Pharma Positioning
Antares Pharma Positioning Antares Pharma, Inc., is uniquely positioned as an emerging specialty pharmaceutical company focused on leveraging its global product pipeline and drug delivery platforms to be commercially focused on creating and improving value-added products and systems of drugs and dru
Slide 6: Antares Pharma Business Model
Antares Pharma Business Model “Taking Control of Our Own Destiny” “Guerilla” market approved products (VISION®, ibuprofen) Advance products to the latest development stage possible: – Niche products in key therapeutic areas of women’s health, pain, CNS – Partner more complex products or costly progr
Slide 7: Recent History & Milestones
Recent History & Milestones Formed January 2001 by business combination of Permatec and Medi-Ject Headquarters in Exton, PA; Operations in Minneapolis and Basel Founder and Chairman, Dr. Jacques Gonella Launched Medi-Jector VISION® in 1999; today the leader in needle-free September 2003: Announced w
Slide 8: Products, Platforms and Pipelines
Products, Platforms and Pipelines
Slide 9: Technology Platforms
Technology Platforms Transdermal Drug Delivery-ATD™Gels Systemic Transdermal Gel Technology (ATD™) ATD™ Single Gels ATD™ Combination Gels Local Topical Delivery Technology Fast Melting Tablets Easy Tec™ Injection Devices Mini-Needle Disposable Injectors (AJ Platform) Vibex™ Needle-Free Reusable Inje
Slide 10: Transdermal Drug Delivery: ATD Gels
Transdermal Drug Delivery: ATD™ Gels (Advanced Transdermal Delivery) Patented gel formulation technology Creates sub-dermal reservoir of drug for systemic delivery over 24 hours More than 15 years of scientific experience in gel technology Successfully developed and partnered several hormone-based A
Slide 11: Fast-Melt Tablets – Easy Tec
Fast-Melt Tablets – Easy Tec™ Patented oral tablet Disintegrates and dissolves rapidly in saliva Ease of manufacture, packaging tech transfer and time to market Important for patients who have difficulty swallowing Therapeutic areas include pain, Alzheimer’s, analgesics, CNS 2002 sector revenues > $
Slide 12: Injection Devices: Disposable Mini-Needle Injectors
Injection Devices: Disposable Mini-Needle Injectors Vibex™ (AJ platform) Single use, prefilled and disposable Mini-needle always hidden Standard Hypak prefilled syringe or prefilled containers General disposal Can deliver variable doses Cost effective Provides competitive advantage Negotiating exclu
Slide 13: Injection Devices: Reusable Needle-Free Technology
Injection Devices: Reusable Needle-Free Technology (Vision™MJ Platform) VISION® marketed since 1999 for insulin and hGH Uses spring to pressurize liquid drug and force it through very small orifice Thin column of fluid penetrates skin and deposited in subcutaneous tissue Targeted to growing protein
Slide 14: Partnered Formulation (Transdermal) Products
Corporate Partnered Formulation (Transdermal) Products Formulation Development Preclinical Testing Clinical Phase I/II Clinical Phase III Regulatory Submission Commercialization License Status Ibuprofen Gel (pain, inflammation) Available N.A., Asia Pacific parts EU Estradiol Patch Licensed in (hormo
Slide 15: Device Products
Device Products Concept Prototype for Design Manufacturing Regulatory Commercialization Clinical Finalization Scale-Up Submission Evaluation VisionRfor Insulin (needle-free injector) Antares Pharma-in market VisionRfor hGH (needle-free injector) Ferring-Europe, U.S.; JCR - Japan - launch late 2004 S
Slide 16: Specialty Pharma Products
Specialty Pharma Products Formulation Preclinical Clinical Phase III (where necessary) Regulatory Commercialization Development Testing Phase I / II necessary) Submission Oxybutynin ATDTM gel (urinary incontinence) Gel Product 1 ATDTM *Estradiol ATDTM gel (hormone therapy) *Testosterone ATDTM gel (f
Slide 17: Alliances, Partnerships and Markets
Alliances, Partnerships and Markets
Slide 18: Established Corporate Partners
Established Corporate Partners
Slide 19: Insulin Injection Opportunity
Insulin Injection Opportunity Progress recognized with milestone payment in December Worldwide 150m with diabetes (growing to 300m by 2025); approximately 10-12m insulin users worldwide 17m patients with diabetes in the US; 4m taking insulin Lilly insulin sales in 2002: $1.8b.Lilly U.S. market share
Slide 20: Estimated Needle-Free Injection Sales
Estimated Needle-Free Injection Sales (in Millions) 450 400 350 300 250 200 150 50 0 $10.3 $425 $195 $230 all other 46% Insulin 54% 2002 2007 Source: Greystone Associates, Needle-free Injection, June 2003
Slide 21: Transdermal Testosterone Gel for Women Opportunity
Transdermal Testosterone Gel for Women (Female Sexual Dysfunction) Opportunity Currently no Rx product available to treat FSD 43% prevalence of sexual dysfunction in females versus 31% in males Modest estimate of U.S.market potential of $2.0 billion; other estimates as much as $4.0 billion Several d
Slide 22: Results of Phase II Study for Testosterone Gel for Women
Results of Phase II Study for Testosterone Gel for Women Announced September 22, 2004: Results from double-blind, placebo-controlled Phase II study with LibiGel™ were released Conducted in the U.S. with 46 hysterectomized women with low sexual desire and activity No serious adverse events and no dis
Slide 23: Oxybutynin Gel for Treatment of Overactive Bladder Syndrome
Oxybutynin Gel for Treatment of Overactive Bladder Syndrome OBS estimated to affect 16 -18% of adults in U.S. (19m) and Europe with higher percentages reported in Asia Products currently used have side effects such as dry mouth (23-24%), dry eyes, blurred vision and constipation Market estimated to
Slide 24: Transdermal Delivery Market
Transdermal Delivery Market US$ (Billions) 14 12 10 8 6 4 2 0 $8.0 $12.7 2002 2005 Source: Jain PharmaBiotech –November 2002
Slide 25: Financial Overview
Financial Overview 4e antares a
Slide 26: Gross Revenues
Gross Revenues $ Millions 6 5 4 3 2 1 0 2001 2002 2003 Product Sales Development Fees Licensing Milestones Total Revenues
Slide 27: Antares Pharma Financial Summary as of June 30, 2004
Antares Pharma – Financial Summary as of June 30, 2004 2004 YTD gross revenues $1.4m Cash & cash equivalents $13.15m Shares outstanding 38m Fully diluted shares outstanding 62m Debt None Market cap at 09-24-2004 $60.3 52 week share price range (at 09-24-2004) $.60—$2.01
Slide 28: Antares Pharma Share Volume Moving Average Year to Date
Antares Pharma – Share Volume Moving Average Year to Date 900,000 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 0 10 Day Moving Ave 30 Day Moving Ave Jan-04 Jan-04 Jan-04 Jan-04 Jan-04 Feb-04 Feb-04 Feb-04 Feb-04 Mar-04 Mar-04 Mar-04 Mar-04 Apr-04 Apr-04 Apr-04 Apr-04 Apr-04 May-04
Slide 29: Antares Pharma Share Price Moving Average Year to Date
Antares Pharma – Share Price Moving Average Year to Date 1.600 1.400 1.200 1.000 0.800 0.600 0.400 0.200 0.000 10 Day Moving Ave 30 Day Moving Ave Jan-04 Jan-04 Jan-04 Feb-04 Feb-04 Mar-04 Mar-04 Apr-04 Apr-04 May-04 May-04 Jun-04 Jun-04 Jul-04 Jul-04 Jul-04 Aug-04 Aug-04 Sep-04 Sep-04
Slide 30: Summary and Investment Rationale
Summary and Investment Rationale Antares Pharma is an emerging specialty pharma company with: A global vision and opportunity including a major international presence A broad array of synergistic platforms to exploit Established alliances and partnerships with big and specialty pharma Significant op
Slide 31: Thank you
Drugs don’t work if people don’t take them—C. Everett koop Thank you
Antares Pharma — UBS Global Life Sciences Conference 2004 on 6ix